FDA Approves Gene Therapy Treatments for Sickle Cell Disease: A Beacon of Hope in the Battle Against SCD
Exciting news emerged from the Food and Drug Administration (FDA) headquarters on December 8, 2023. The FDA has approved two groundbreaking cell-based gene therapies (Casgevy and Lyfgenia) for treating sickle cell disease (SCD). This milestone achievement opens a new chapter in the battle against this debilitating disease, offering hope to countless individuals and their families …